Baricitinib study for kids with juvenile arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already joined an earlier baricitinib study for juvenile idiopathic arthritis
- You must not have permanently stopped baricitinib during that earlier study
- You must not have had an allergic reaction to baricitinib in the earlier study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study looks at immune cells in the blood of people with juvenile idiopathic arthritis (JIA) to see how different treatments affect them. It may help doctors understand the disease better and improve future care.
This trial tests whether baricitinib, a pill that lowers inflammation, can also help reduce blood-clotting risk in people with rheumatoid arthritis. It may help if your arthritis is still active despite current treatment, and you have no other major health conditions.
This trial studies the use of a medication called tofacitinib in children and teenagers with juvenile idiopathic arthritis (JIA), a type of arthritis that starts in childhood. The goal is to see if the drug helps reduce joint pain and inflammation.
This trial tests whether baricitinib can improve severe alopecia areata (patchy, autoimmune hair loss) in children and teens. It’s meant for people who have had long-lasting, severe hair loss and have tried other treatments without enough benefit.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.